translational-research
(3)
Tahamtan Ahmadi
Tahamtan Ahmadi built his career in the hard middle of biotechnology - where a scientific idea must survive evidence, regulation, and scale. At Genmab, his remit now stretches from discovery to medicine, and his public philosophy keeps returning to curiosity, collaboration, and patient impact.
Roy Maute
Roy Maute is co-founder and CEO of Pheast Therapeutics, a clinical-stage biotech in Redwood City, CA, developing macrophage-targeted cancer immunotherapies. Trained at UC Berkeley, Columbia (PhD, Genetics), and Stanford (postdoc under Irving Weissman), Maute has built a career at the intersection of innate immunology and drug development. Before Pheast, he co-founded Ab Initio Biotherapeutics (acquired by Ligand in 2019) and led translational research at Forty Seven Inc. ahead of its $4.9B acquisition by Gilead in 2020. At Pheast, he is advancing PHST001, a novel anti-CD24 antibody that teaches macrophages to eat cancer cells, currently in Phase 1 clinical trials with FDA Fast Track Designation for ovarian cancer.
Sandra Pérez Baos
Sandra Pérez Baos, Ph.D. is a Senior Associate at 2048 Ventures, a NYC- and Boston-based thesis-driven early-stage VC firm that closed an oversubscribed $82M Fund III in January 2026. A scientist turned investor, she brings a decade of hands-on experience in translational immunology and molecular biology research - first as a postdoctoral researcher at NYU Grossman School of Medicine, then as a founding leader at Nucleate New York, and later as a fellow with NYU's technology commercialization office. At 2048 Ventures she leads biotech and health investments at pre-seed and seed stages, writing checks from $500K to $3M into companies building the next generation of platform biology, drug delivery, diagnostics, and digital health.